Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension

Journal of the American College of Cardiology

Volumn 43, Issue 12 SUPPL., 2004, Pages S81-S88

  Galiè, Nazzareno ^a   Seeger, Werner ^b   Naeije, Robert ^c   Simonneau, Gerald ^d   Rubin, Lewis J ^e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

calcium channel blocker; CCB; endothelin receptor A; endothelin 1 receptor antagonist; ERA; ET A; idiopathic pulmonary arterial hypertension; intravenous; IPAH; IV; New York Heart Association; NYHA; PAH; pulmonary arterial hypertension; RCT

Indexed keywords

AMBRISENTAN; ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL; SITAXSENTAN; UNIPROST; VASODILATOR AGENT;

ALGORITHM; ANTICOAGULATION; BALLOON ATRIAL SEPTOSTOMY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG USE; EISENMENGER COMPLEX; EVALUATION; EVIDENCE BASED MEDICINE; FLUID RETENTION; HEART FAILURE; HEART SURGERY; HEMODYNAMICS; HUMAN; HYPOXEMIA; INTERMETHOD COMPARISON; LUNG TRANSPLANTATION; ORGANIZATION; OXYGEN THERAPY; POPULATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RATING SCALE; SCLERODERMA; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 2942544581     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.02.038     Document Type: Conference Paper

References (37)

1. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., Frye R.L. Primary pulmonary hypertension Natural history and the importance of thrombosis. Circulation. 70:1984;580-587
2. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension (see comments). N Engl J Med. 327:1992;76-81
3. Frank H., Mlczoch J., Huber K., Schuster E., Gurtner H.P., Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 112:1997;714-721
4. Sandoval J., Aguirre J.S., Pulido T., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 164:2001;1682-1687
5. Rich S., Brundage B.H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 76:1987;135-141
6. Raffy O., Azarian R., Brenot F., et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 93:1996;484-488
7. Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 99:1999;1197-1208
8. Sitbon O., Humbert M., Ioos V., et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension (abstr)? Am J Respir Crit Care Med. 167:2003;A440
9. Nootens M., Kaufmann E., Rich S. Short-term effectiveness of nifedipine in secondary pulmonary hypertension. Am J Cardiol. 71:1993;1475-1476
10. Sandoval J., Rothman A., Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med. 22:2001;547-560
11. Klepetko W., Mayer E., Sandoval J., et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol. 43:(Suppl S):2004;73S-80S
12. Sandoval J., Gaspar J., Pulido T., et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 32:1998;297-304
13. Hertz M.I., Taylor D.O., Trulock E.P., et al. The registry of the International Society for Heart and Lung Transplantation: nineteenth official report 2002. J Heart Lung Transplant. 21:2002;950-970
14. Rubin L.J., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 112:1990;485-491
15. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group (see comments). N Engl J Med. 334:1996;296-302
16. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial (see comments). Ann Intern Med. 132:2000;425-434
17. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 165:2002;800-804
18. McLaughlin V.V., Gaine S.P., Barst R.J., et al. Efficacy and safety of treprostinil An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 41:2003;293-299
19. Galie N., Humbert M., Vachiery J.L., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 39:2002;1496-1502
20. Barst R.J., McGoon M., McLaughlin V.V., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 41:2003;2119-2125
21. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med. 347:2002;322-329
22. Higenbottam T.W., Butt A.Y., Dinh-Xaun A.T., Takao M., Cremona G., Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart. 79:1998;175-179
23. Channick R., Badesch D.B., Tapson V.F., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension A placebo-controlled study. J Heart Lung Transplant. 20:2001;262-263
24. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896-903
25. Galie N., Hinderliter A.L., Torbicki A., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 41:2003;1380-1386
26. Barst R., Langleben D., Frost A., et al. Sitaxsentan, a selective ETA receptor antagonist, improves exercise capacity and NYHA functional class in pulmonary arterial hypertension (abstr). Am J Respir Crit Care Med. 167:2003;A440
27. Barst R., Langleben D., Frost A., et al. Sitaxsentan, a selective ETA antagonist, improves cardiopulmonary hemodynamics in pulmonary arterial hypertension (abstr). Am J Respir Crit Care Med. 167:2003;A273
28. Barst R.J., Rich S., Widlitz A., Horn E.M., McLaughlin V., McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension Open-label pilot study. Chest. 121:2002;1860-1868
29. Rubin LJ, Galie N, Badesch BD, et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2004. In press.
30. Prasad S., Wilkinson J., Gatzoulis M.A. Sildenafil in primary pulmonary hypertension. N Engl J Med. 343:2000;1342
31. Bhatia S., Frantz R.P., Severson C.J., Durst L.A., McGoon M.D. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc. 78:2003;1207-1213
32. Michelakis E.D., Tymchak W., Noga M., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 108:2003;2066-2069
33. Sastry BKS, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149-53.
34. Humbert M., Barst R., Robbins I., et al. Safety and efficacy of bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension (abstr). Am J Respir Crit Care Med. 167:2003;A441
35. Hoeper M, Taha N, Bekjarova A, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving non-parenteral prostanoids. Eur Respir J 2003;330-4.
36. Ghofrani H.A., Rose F., Schermuly R.T., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 42:2003;158-164
37. Committee for Practice Guidelines (CPG) of the European Society of Cardiology. Recommendations for task force creation and report production. A document for task force members and expert panels responsible for the creation and production of guidelines and expert consensus documents Committee for Practice Guidelines (CPG) of the European Society of Cardiology. Available at the European Society of Cardiology Website 2003: http://www.escardio.org/scinfo/ Recommendations.pdf. Accessed in March 2004.